Gliflozins on HF in Regurgitant Rheumatic Heart

Heart Failure Clinical Trial

Official title: Effect of Gliflozins on Heart Failure Due to Regurgitant Rheumatic Valve Disease

Status Not yet recruiting

Clinical Trial Summary

The objective of this trial is to detect impact of Gliflozin on patients with heart failure due to reurgitant rheumatic valve disease

Clinical Trial Description

• Rheumatic heart disease is a chronic sequel of acute rheumatic fever caused by group A β hemolytic Streptococcal pharyngitis and possibly pyoderma, which mimics molecular heart structures so the immune response leads to carditis and valvular heart damage. Damage to valves cause mitral and/or aortic regurgitation, or in long-standing stenosis. Complications of rheumatic heart disease include heart failure, embolic stroke, endocarditis and atrial fibrillation .

• Heart failure (HF) is a progressive syndrome characterised by the inability of the heart to provide adequate blood supply to meet the metabolic demand of different tissues .

• The recent ESC/AHA/ACC guidelines of HF set medications as class 1 for the HF therapy as ACE-I/ ARNI/beta-blocker/MRA/ SGLT2 I as they reduced the risk of cardiovascular death and worsening HF in patients with HFrEF , Unless contraindicated or not tolerated.

• Empagliflozin is an orally available inhibitor sodium glucose co-transporter 2 receptor (SGLT-2), empagliflozin exerts its effect by preventing sodium and glucose reabsorption from proximal convoluted tubules. This leads to increased urinary sodium and glucose excretion, This is associated with a modest osmotic diuresis, blood pressure lowering effect, improvement in arterial stiffness , and decrease in heart rate.

• DAPA-HF trial shows: The primary outcome of cardiovascular death, HF hospitalization, for dapagliflozin vs. placebo, was 16.3% vs 21.2% (p < 0.001).

• EMPA-REG OUTCOME trial shows: The primary outcome, cardiovascular death or HF hospitalization, for empagliflozin vs. placebo, was 19.4% vs. 24.7% ( p < 0.001). ;

Related Conditions & MeSH terms

• Heart Diseases
• Heart Failure
• Rheumatic Diseases
• Rheumatic Heart Disease

• NCT number: NCT06097585
• Study type: Observational
• Source: Assiut University
• Contact: Ahmed Y Dandrawy, Bachelor
• Phone: +201013086863
• Email: ahmed_youssef200@yahoo.com
• Status: Not yet recruiting
• Start date: December 1, 2023
• Completion date: April 1, 2025